Latest Insider Transactions at Palisade Bio, Inc. (PALI)
This section provides a real-time view of insider transactions for Palisade Bio, Inc. (PALI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PALISADE BIO, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PALISADE BIO, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2024
|
Donald Allen Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
388
+34.77%
|
-
|
|
Nov 21
2024
|
Binxian Wei Director |
BUY
Exercise of conversion of derivative security
|
Direct |
388
+31.21%
|
-
|
|
Jun 11
2024
|
Donald Allen Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
340
+50.0%
|
-
|
|
Jun 11
2024
|
Binxian Wei Director |
BUY
Exercise of conversion of derivative security
|
Direct |
465
+49.89%
|
-
|
|
May 28
2024
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,033
-5.46%
|
$8,132
$4.76 P/Share
|
|
May 28
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,068
+15.81%
|
-
|
|
May 28
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,271
-16.7%
|
$5,084
$4.76 P/Share
|
|
May 28
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,290
+34.95%
|
-
|
|
May 28
2024
|
Donald Allen Williams Director |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$4,000
$4.86 P/Share
|
|
May 24
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
1,000
+10.6%
|
$4,000
$4.81 P/Share
|
|
May 20
2024
|
John David Finley CEO, CFO, Director |
BUY
Grant, award, or other acquisition
|
Direct |
666
+8.22%
|
$2,664
$4.97 P/Share
|
|
May 06
2024
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
128
-0.95%
|
$1,024
$8.46 P/Share
|
|
May 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+3.17%
|
-
|
|
May 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-8.2%
|
$1,096
$8.46 P/Share
|
|
May 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
460
+21.12%
|
-
|
|
Mar 11
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,558
+5.43%
|
-
|
|
Feb 09
2024
|
James R Neal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Stephanie Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.63%
|
-
|
|
Feb 08
2024
|
Robert J. Trenschel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Cristina Csimma Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.47%
|
-
|
|
Feb 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,642
+3.57%
|
-
|
|
Feb 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,153
-21.94%
|
$0
$0.44 P/Share
|
|
Feb 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,891
+28.53%
|
-
|
|
Feb 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.57%
|
$0
$0.47 P/Share
|
|
Jan 31
2024
|
Donald Allen Williams Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+25.0%
|
$0
$0.6 P/Share
|
|
Jan 31
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
10,000
+11.81%
|
$0
$0.56 P/Share
|
|
Jan 03
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,309
+1.98%
|
-
|
|
Dec 11
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,559
+8.07%
|
-
|
|
Nov 20
2023
|
John David Finley CEO, CFO, Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.75%
|
$0
$0.51 P/Share
|
|
Nov 07
2023
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,630
-35.78%
|
$0
$0.54 P/Share
|
|
Nov 06
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+6.78%
|
-
|
|
Nov 06
2023
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,556
+50.0%
|
-
|
|
Oct 04
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-0.89%
|
$0
$0.55 P/Share
|
|
Oct 03
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,309
+2.84%
|
-
|
|
Sep 27
2023
|
Donald Allen Williams Director |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$0
$0.54 P/Share
|
|
Sep 27
2023
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
15,000
+25.69%
|
$0
$0.54 P/Share
|
|
Sep 14
2023
|
Robert J. Trenschel Director |
SELL
Open market or private sale
|
Direct |
300
-100.0%
|
$0
$0.64 P/Share
|
|
Sep 13
2023
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
15,000
+34.57%
|
$0
$0.66 P/Share
|
|
Sep 12
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,792
-11.8%
|
$0
$0.66 P/Share
|
|
Sep 11
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,558
+26.79%
|
-
|
|
Aug 11
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,040
-9.75%
|
$0
$0.7 P/Share
|
|
Aug 06
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+23.91%
|
-
|
|
Jul 06
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
389
-5.13%
|
$389
$1.76 P/Share
|
|
Jul 03
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,309
+14.72%
|
-
|
|
Jun 13
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,050
-14.34%
|
$1,050
$1.54 P/Share
|
|
Jun 12
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,475
+32.18%
|
-
|
|
Apr 03
2023
|
Robert Curtis Mc Rae Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
270
-30.17%
|
$540
$2.0 P/Share
|
|
Apr 03
2023
|
Robert Curtis Mc Rae Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
655
+42.26%
|
-
|
|
Apr 03
2023
|
John David Finley CEO, CFO, Director |
SELL
Payment of exercise price or tax liability
|
Direct |
435
-10.16%
|
$870
$2.01 P/Share
|
|
Apr 03
2023
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,309
+23.41%
|
-
|